Vigilare Wealth Management’s Marker Therapeutics MRKR Stock Holding History

Vigilare Wealth Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,250	Closed	-$173K	–	191
2021 Q3	$173K	Sell	10,250 -800	-7%	-$16.4K	0.11%	186
2021 Q2	$308K	Sell	11,050 -1,710	-13%	-$45K	0.19%	140
2021 Q1	$286K	Sell	12,760 -1,415	-10%	-$32.4K	0.2%	140
2020 Q4	$206K	Buy	14,175 +1,330	+10%	+$20.6K	0.2%	135
2020 Q3	$193K	Buy	12,845 +2,500	+24%	+$45.6K	0.2%	125
2020 Q2	$214K	Sell	10,345 -5,041	-33%	-$110K	0.22%	104
2020 Q1	$292K	Buy	15,386 +3,606	+31%	+$91.9K	0.35%	78
2019 Q4	$306K	Buy	+11,780	New	+$429K	0.2%	105

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vigilare Wealth Management's MRKR Position: Q4 2021 in Review

Vigilare Wealth Management sold out of Marker Therapeutics (MRKR) in Q4 2021, closing a stake of 10,250 shares — an estimated $173K sold.

Vigilare Wealth Management first reported a position in MRKR in Q4 2019 and held it in 8 quarters. The position peaked at $308K in Q2 2021. 64 funds tracked by Wall St. Rank hold MRKR as of Q4 2021.

Vigilare Wealth Management reported no remaining Marker Therapeutics position as of Q4 2021 after selling out during the quarter.
Vigilare Wealth Management sold 10,250 Marker Therapeutics shares in Q4 2021, an estimated $173K.
Vigilare Wealth Management first reported a position in Marker Therapeutics in Q4 2019 and held it in 8 quarters.
Vigilare Wealth Management's Marker Therapeutics position peaked at $308K in Q2 2021.
64 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2021.

Based on Vigilare Wealth Management's 13F filing for Q4 2021, filed 7 Jan 2022.